Amarin (AMRN) Vascepa Prescriptions Still Showing Strong Growth (GSK)
Tweet
Share
E-mail
Get Alerts AMRN Hot Sheet
Price: $14.07 -0.57%
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Amarin (Nasdaq: AMRN) is ticking higher early following new Vascepa data from Symphony Health, compiled by Bloomberg Industries (BI).
For its 22nd week on the market, Vascepa prescriptions rose 16 percent to 3,879.0 for the week ended June 7th. That compares with 3,336.0 prescriptions the prior week.
Vascepa competitor, GlaxoSmithKline's (NYSE: GSK) Lovaza, saw just a 12 percent gain in prescriptions to 97,945.0.
No channel blocking or change in projection methodology has been applied to Vascepa since launch, BI said.
Ahead of the bell, Amarin is up 2.4 percent.
For its 22nd week on the market, Vascepa prescriptions rose 16 percent to 3,879.0 for the week ended June 7th. That compares with 3,336.0 prescriptions the prior week.
Vascepa competitor, GlaxoSmithKline's (NYSE: GSK) Lovaza, saw just a 12 percent gain in prescriptions to 97,945.0.
No channel blocking or change in projection methodology has been applied to Vascepa since launch, BI said.
Ahead of the bell, Amarin is up 2.4 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- McGraw Hill (MH) PT Raised to $15 at UBS
- Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
